{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:05:46Z","timestamp":1790247946587,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,24]],"date-time":"2027-09-24T00:00:00Z","timestamp":1821744000000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002014"],"award-info":[{"award-number":["UL1 TR002014"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR002379"],"award-info":[{"award-number":["KL2TR002379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR00045"],"award-info":[{"award-number":["UL1 TR00045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA049721"],"award-info":[{"award-number":["DA049721"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019874","name":"Children's Hospital Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaac.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:16:32Z","timestamp":1766020592000},"page":"1273-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Attention-Deficit\/Hyperactivity Disorder Treatment Patterns and Association With Clinical Outcomes in Adolescents and Young Adults with Co-Occurring Attention-Deficit\/Hyperactivity Disorder and Substance Use Disorder: A Retrospective Analysis"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-0643","authenticated-orcid":false,"given":"Raman","family":"Baweja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-1286","authenticated-orcid":false,"given":"Daniel A.","family":"Waschbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0211-8373","authenticated-orcid":false,"given":"Felix M.","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-9426","authenticated-orcid":false,"given":"Ritika","family":"Baweja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7062-8192","authenticated-orcid":false,"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-570X","authenticated-orcid":false,"suffix":"III","given":"William E.","family":"Pelham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-3755","authenticated-orcid":false,"given":"Brooke S.G.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-8503","authenticated-orcid":false,"given":"Timothy E.","family":"Wilens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-3417","authenticated-orcid":false,"given":"James G.","family":"Waxmonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jaac.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40272-015-0144-2","article-title":"Impact of attention-deficit hyperactivity disorder on school performance: what are the effects of medication?","volume":"17","author":"Baweja","year":"2015","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.jaac.2025.12.003_bib3","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7340a1","article-title":"Attention-deficit\/hyperactivity disorder diagnosis, treatment, and telehealth use in adults\u2014National Center for Health Statistics Rapid Surveys System, United States, October\u2013November 2023","volume":"73","author":"Staley","year":"2024","journal-title":"MMWR. Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijerph20021275","article-title":"Prevalence of attention deficit hyperactivity disorder (ADHD) among substance use disorder (SUD) populations: meta-analysis","volume":"20","author":"Rohner","year":"2023","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.jaac.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1177\/1087054715626511","article-title":"Comorbidity of adult ADHD and its subtypes with substance use disorder in a large population-based epidemiological study","volume":"23","author":"Capusan","year":"2019","journal-title":"J Atten Disord"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5498\/wjp.v13.i3.84","article-title":"Identification and treatment of individuals with attention-deficit\/hyperactivity disorder and substance use disorder: an expert consensus statement","volume":"13","author":"Young","year":"2023","journal-title":"World Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.chc.2022.01.005","article-title":"ADHD and substance use disorders in young people: considerations for evaluation, diagnosis, and pharmacotherapy","volume":"31","author":"Taubin","year":"2022","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000487767","article-title":"International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit\/hyperactivity disorder","volume":"24","author":"Crunelle","year":"2018","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.jaac.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jsat.2014.11.005","article-title":"Long-term outcomes of pharmacologically treated vs non-treated adults with ADHD and substance use disorder: a naturalistic study","volume":"51","author":"Muld","year":"2015","journal-title":"J Substance Abuse Treat"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.003_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12849","article-title":"Investigating causality between liability to ADHD and substance use, and liability to substance use and ADHD risk, using Mendelian randomization","volume":"26","author":"Treur","year":"2021","journal-title":"Addict Biol"},{"key":"10.1016\/j.jaac.2025.12.003_bib11","first-page":"1","article-title":"Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study","author":"O'Nions","year":"2025","journal-title":"Br J Psychiatry"},{"issue":"9983","key":"10.1016\/j.jaac.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","article-title":"Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study","volume":"385","author":"Dalsgaard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-017-1463-3","article-title":"Adult ADHD and comorbid disorders: clinical implications of a dimensional approach","volume":"17","author":"Katzman","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3390\/jcm12093096","article-title":"Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician","volume":"12","author":"Barbuti","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jaac.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamapsychiatry.2025.0054","article-title":"Prescription stimulant use, misuse, and use disorder among US adults aged 18 to 64 years","volume":"82","author":"Han","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","article-title":"Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies","volume":"59","author":"Faraone","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.jaac.2025.12.003_bib19","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.3928\/00485713-20250729-01","article-title":"Management of attention-deficit\/hyperactivity disorder in transitional-aged youth with comorbid substance use disorder","volume":"55","author":"Baweja","year":"2025","journal-title":"Psychiatr Ann"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamapsychiatry.2023.2157","article-title":"Association between stimulant treatment and substance use through adolescence into early adulthood","volume":"80","author":"Molina","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","article-title":"ADHD medication and substance-related problems","volume":"174","author":"Quinn","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.01.006","article-title":"A literature review and meta-analysis on the effects of ADHD medications on functional outcomes","volume":"123","author":"Boland","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.003_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/cap.2022.0016","article-title":"The impact of pharmacotherapy of childhood-onset psychiatric disorders on the development of substance use disorders","volume":"32","author":"Wilens","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.003_bib24","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13598","article-title":"Pharmacotherapy for attention-deficit\/hyperactivity disorder and retention in outpatient substance use disorder treatment: a retrospective cohort study","volume":"82","author":"Kast","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","article-title":"Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a Swedish nationwide cohort of 13 965 patients","volume":"80","author":"Hartikainen","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2025.12.003_bib26","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14m09559","article-title":"Nonmedical stimulant use in college students: association with attention-deficit\/hyperactivity disorder and other disorders","volume":"77","author":"Wilens","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.003_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcp.12045","article-title":"Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit\/hyperactivity disorder and addiction","volume":"77","author":"P\u00e9rez de los Cobos","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.003_bib28","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-057992","article-title":"Committee on Substance Use and Prevention, Committee on Child Health Financing. Improving substance use prevention, assessment, and treatment financing to enhance equity and improve outcomes among children, adolescents, and young adults","volume":"150","author":"Camenga","year":"2022","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jaac.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jaac.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","article-title":"Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: a randomized clinical trial","volume":"72","author":"Levin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2018.03.043","article-title":"How treatment improvement in ADHD and cocaine dependence are related to one another: a secondary analysis","volume":"188","author":"Levin","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.003_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0269881109103113","article-title":"Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse","volume":"23","author":"Jasinski","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1087054715569280","article-title":"Treatments for adolescents with comorbid ADHD and substance use disorder: a systematic review","volume":"24","author":"Zaso","year":"2020","journal-title":"J Atten Disord"},{"issue":"1-2","key":"10.1016\/j.jaac.2025.12.003_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.drugalcdep.2008.02.009","article-title":"Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders","volume":"96","author":"Wilens","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.jaac.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/cap.2005.15.777","article-title":"Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit\/hyperactivity disorder and mood disorders","volume":"15","author":"Solhkhah","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2025.12.003_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2022.107329","article-title":"The effect of varenicline and bupropion on smoking cessation: a network meta-analysis of 20 randomized controlled trials","volume":"131","author":"Guo","year":"2022","journal-title":"Addict Behav"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v21n02_01","article-title":"Bupropion treatment for cocaine abuse and adult attention-deficit\/hyperactivity disorder","volume":"21","author":"Levin","year":"2002","journal-title":"J Addict Dis"},{"key":"10.1016\/j.jaac.2025.12.003_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083658","article-title":"ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials","volume":"390","author":"Zhang","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.003_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2859","article-title":"Attention-deficit\/hyperactivity disorder medications and work disability and mental health outcomes","volume":"7","author":"Taipale","year":"2024","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.jaac.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jama.2024.0851","article-title":"ADHD pharmacotherapy and mortality in individuals with ADHD","volume":"331","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jaac.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2025.1281","article-title":"Increased prescribing of attention-deficit\/hyperactivity disorder medication and real-world outcomes over time","volume":"82","author":"Li","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.003_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/cap.2024.0022","article-title":"From consensus statement to pills to pixels: new innovations in attention-deficit\/hyperactivity disorder care","volume":"34","author":"Baweja","year":"2024","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/10870547241288744","article-title":"Adolescent-reported changes in provider behavior following pediatrician training in stimulant diversion prevention: results from a cluster randomized controlled trial","volume":"29","author":"Molina","year":"2025","journal-title":"J Atten Disord"},{"key":"10.1016\/j.jaac.2025.12.003_bib44","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaac.2025.12.003_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112167","article-title":"Association of antidiabetic medications with depression risk and all-cause mortality in type 2 diabetes: a TriNetX-Based cohort study","volume":"223","author":"Chen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2007","journal-title":"Am J Epidemiol"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856725022324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856725022324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:25:16Z","timestamp":1790245516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856725022324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0890856725022324"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2025.12.003","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attention-Deficit\/Hyperactivity Disorder Treatment Patterns and Association With Clinical Outcomes in Adolescents and Young Adults with Co-Occurring Attention-Deficit\/Hyperactivity Disorder and Substance Use Disorder: A Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}